A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
PHASE2Active, not recruitingINTERVENTIONAL
Enrollment
120
Participants
Timeline
Start Date
February 18, 2025
Primary Completion Date
November 30, 2025
Study Completion Date
December 31, 2025
Conditions
Treatment of Lipoprotein Disorder
Interventions
DRUG
HRS-5346
HRS-5346
DRUG
Placebo
Placebo
Trial Locations (1)
100000
Peking University Third Hospital, Beijing
All Listed Sponsors
lead
Shandong Suncadia Medicine Co., Ltd.
INDUSTRY
NCT06816264 - A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | Biotech Hunter | Biotech Hunter